Colchicine as a potential therapeutic option in COVID – 19 hospitalized patients

Abstract

OVID-19 is a newly emerged disease that has become a global public health challenge. Due to a lack of knowledge about the virus, a significant number of potential targets for using a particular drug have been proposed. Aim and objectives To compare the role of colchicine as a potential therapeutic option in COVID – 19 confirmed cases in addition to the standard of care versus the standard of care alone. This retrospective cohort study was conducted on 100 positive nasopharyngeal swabs PCR for SARS- CoV-2 viral infection who were admitted to Ain Shams Field Hospital. (50 in each): • Group A: includes patients who received colchicine (An initial dose of 1.5 mg orally on the first day, followed by 0.5 mg every 12 hours on days 2 to 7 and continuing with 0.5 mg a day until completing 14 days). plus standard treatment (hydroxychloroquine 400 ml /12 hr orally loading dose on the first day then 200ml/12 hr orally for 5 or 10 days plus Azithromycine 500ml/24 hr orally for 5 days). • Group B: includes patients who received standard of care (hydroxychloroquine 400 ml /12 hr orally loading dose on the first day then 200ml/12 hr orally for 5 or 10 days plus Azithromycine 500ml/24 hr orally for 5 days).